PLSE PULSE BIOSCIENCES, INC. Insider Trading

CEO Paul Laviolette's first open-market share purchase in 36 months: 15,000 shares while stock trades below 52-week high.

Paul Laviolette, the company's Chief Executive Officer, purchased shares on the open market for the first time in at least three years, a meaningful shift from his prior Form 4 activity which consisted exclusively of stock-based compensation transactions. The purchase occurred while the stock trades notably below its 52-week high, creating a meaningful distinction between what he received as part of his compensation package versus what he chose to buy with personal capital. The company remains unprofitable with a significant net loss in its most recent period, yet Laviolette is choosing to increase his ownership at current price levels rather than remain passive. As the CEO, his willingness to deploy personal capital into the business at this point in the stock's trajectory — after a multi-month decline — warrants attention from investors tracking leadership conviction, particularly given the rarity of this action in his filing history.

Director and 10% owner Robert Duggan purchases $13M in PLSE shares as stock trades below 52-week highs; 26th open-market buy in 36 months.

Robert Duggan, a director and major shareholder, has committed roughly $13 million to acquire shares at prices between the 52-week low and current levels, expanding his position significantly. This represents his 26th open-market purchase over the past three years—an unbroken pattern of accumulation with no offsetting sales. Duggan's prior purchases at this company have produced mixed near-term results (four of his previous five buys saw initial gains, but all five trades ultimately declined over a longer timeframe), suggesting his timing has been inconsistent. The company itself remains unprofitable with substantial operating losses, though it is generating meaningful revenue, meaning Duggan is buying a loss-making biotech business at a point when the stock sits notably below its 52-week highs. The scale and consistency of his purchasing activity—combined with his director status and substantial ownership stake—distinguishes this from routine insider trades, though his historical track record of poor long-term outcomes after prior purchases at this same company tempers the signal.

CEO Paul Laviolette's first open-market purchase: 15,000 shares in PLSE at $19.69, signaling personal conviction in biotech facing near-term profitability pressure.

Paul Laviolette, Pulse Biosciences' Chief Executive Officer, has made his first open-market purchase of company shares — a meaningful signal given that his prior Form 4 activity over three years consisted entirely of stock-based compensation transactions. By writing a personal check to acquire shares at an open-market price, he's moving beyond compensation vesting to actively putting capital at risk. The purchase comes as the stock trades notably below its 52-week high, and the company's financials show ongoing losses and limited revenue, making this a contrarian entry point for someone with direct knowledge of operations. This is the clearest available indicator of insider confidence when cash and stock comp are distinguished: Laviolette received equity through employment; now he's choosing to buy more. For a pre-revenue biotech or clinical-stage company, this kind of personal investment by the CEO carries weight precisely because insiders can afford to wait out downturns if they believe in the underlying assets.

Chief Commercial Officer Kevin Danahy sold 60,000 shares of PLSE for $1,410,600 across 3 transactions via 10b5-1 plan

Kevin Patrick Danahy, Chief Commercial Officer at Pulse Biosciences, executed 3 separate sales totaling 60,000 shares for $1,410,600 at prices between $23.37 and $23.63 on February 12, 13, and 17, 2026. This transaction reduces his holdings from 103,298 shares to 43,298 shares—a 58.1% reduction. Critically, this sale is part of a pre-arranged 10b5-1 trading plan adopted on 2025-05-14, meaning it was scheduled in advance rather than discretionary. The planned nature of the trade limits inference about current company fundamentals or management confidence at the time of execution.

Chief Commercial Officer Kevin Patrick Danahy sells 60,000 shares (58.1% of holdings) via pre-arranged 10b5-1 plan

Kevin Patrick Danahy, Chief Commercial Officer, executed 3 separate sales totaling 60,000 shares for $1,403,400.00 across February 9-11, 2026, reducing his stake from 103,298 shares to 43,298 shares. This represents a 58.1% reduction in his post-transaction holdings. The transaction was executed under a pre-arranged 10b5-1 trading plan adopted on 2025-05-14, meaning the timing and volume were scheduled in advance rather than discretionary. The three separate sales occurred at progressively higher prices ($21.45, $23.52, and $25.20), reflecting intraday market movements over the filing period. Since this transaction is governed by a pre-arranged plan, the price progression is a function of market conditions rather than insider timing choice, and investors should focus on the aggregate reduction in executive equity exposure rather than any inference about the officer's forward-looking views.

CTO Darrin Uecker sells 45,000 shares in 2 tranches ($731,200) via pre-arranged 10b5-1 plan

Darrin Uecker, Chief Technology Officer at Pulse Biosciences, executed 2 separate sales totaling 45,000 shares for $731,200.00 at a blended average price of $16.25 on September 16-17, 2025. This transaction reduced his post-transaction holdings to 284,406 shares, a 13.7% reduction from his prior stake of 329,406 shares. The sales were conducted pursuant to a pre-arranged 10b5-1 trading plan adopted on June 12, 2025, meaning the timing and execution were scheduled in advance rather than discretionary. As a scheduled plan transaction, this sale reflects a predetermined liquidation schedule and does not indicate timing-driven decision-making by the CTO.

CTO Uecker sells 75,000 PLSE shares for $1,121,750 across 3 transactions under 10b5-1 plan

Chief Technology Officer Darrin Uecker executed 3 separate sales totaling 75,000 shares for $1,121,750 on September 11, 12, and 15, 2025, at prices ranging from $14.32 to $15.77. This sale reduced his holdings by 37.9%, from 197.9K shares to 122.9K shares post-transaction. The transactions were executed under a pre-arranged 10b5-1 trading plan adopted on 2025-06-12, meaning the sales were scheduled and predetermined rather than discretionary decisions. Since these sales follow an established trading plan, the timing and pricing reflect the plan's predetermined schedule rather than current market conditions or executive judgment.

Director Duggan buys 192,599 shares for $2.8M at $14.48 avg across 3 trades; stock -40.9% from 52-week high.

Robert W. Duggan, Director at PULSE BIOSCIENCES, completed 3 separate purchases totaling 192,599 shares for $2,788,624.34 between September 10–12, 2024, at prices ranging from $14.41 to $14.77. His post-transaction holdings of 47.71M shares represent a modest 0.4% increase. The current market price of $14.52 sits -40.9% below the 52-week high of $24.56, and the stock has declined -13.5% over the past 30 days. Duggan's same-ticker history shows 5 prior buys at PLSE with mixed timing outcomes; 3 of 5 achieved positive 90-day returns, whereas his cross-ticker track record displays an 81.25% 90-day win rate with an average 90d return of +11.9%. The company reported $0.00 revenue in the latest quarter and a $-19.2M net loss, indicating ongoing unprofitability. The transaction signals insider accumulation during a period of material stock decline, but the modest portfolio impact and company's unprofitable state warrant careful monitoring of subsequent developments.

Director Robert W Duggan buys 55,256 shares of PLSE at $17.18; cross-ticker track record shows 93.75% 90d win rate, yet company posts -$12.7M net income with -100% revenue growth.

Robert W Duggan, a director, purchased 55,256 shares at $17.18 on 2024-12-13, adding to his 42.33M-share position. Across his 20 prior open-market buys at other tickers, Duggan has achieved a 93.75% 90-day win rate with avg 90d return of +17.2%. At PLSE specifically, his 3 measurable prior buys have all shown positive 90-day returns (ranging +12.9% to +19.8%), establishing a pattern of well-timed entry points at this ticker. However, PULSE Biosciences itself is in financial distress: latest quarter revenue is $0.00, full-year net income was -$12.7M, and annual revenue growth is -100.0%. While his prior purchase timing on this stock has been accurate, the company's deteriorating fundamentals—shifting from revenue to zero in the latest quarter—represent a material headwind that complicates the traditional interpretation of an insider buy signal.

Director Robert Duggan buys 45,404 shares of PLES at $17.13 despite company burning cash with -$12.7M net income and -100% revenue growth

Director Robert Duggan purchased 45,404 shares at $17.13 for $777,770.52, adding to his substantial 42.27M share position. Notably, this purchase occurs in a context where Pulse Biosciences reported zero quarterly revenue and a full-year net loss of -$12,680,000, with annual revenue declining by -100.0%. While Duggan's cross-ticker track record shows strong execution (93.75% 90-day win rate, avg 90d return +17.2% across 20 prior buys), this metric reflects performance across other securities, not necessarily this specific company's trajectory. The purchase represents only a +0.1% increase to his existing 42.23M holdings, a relatively modest addition given the scale of his current position. The transaction demands scrutiny as to whether it reflects contrarian conviction in a cash-burn scenario, portfolio maintenance of existing exposure, or other strategic intent—distinctions that current filings do not clarify.